Jun Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Guo has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
- Hon-Kan Yip
Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
12 shared publications John Y. Chiang
Department of Computer Science and Engineering National Sun Yat‐Sen University Kaohsiung Taiwan, ROC
9 shared publicationsChuxian Guo
The First Affiliated Hospital, Jinan University
7 shared publicationsShaojie Han
The First clinical Medical college, Jinan University, Guangzhou, China
7 shared publicationsHuimin Zhu
Department of Cardiology, The First Affiliated Hospital,Jinan University, Guangzhou, China
6 shared publicationsJui-Ning Yeh
Department of Cardiology, The First Affiliated Hospital, Jinan University, 613W. Huangpu Avenue, Guangzhou 510630, China
6 shared publications
Latest Publications
- 9 October 2026
- Published by Springer Nature in Journal of Cancer Survivorship
- p. 1-12
Frailty and risk of common chronic diseases among cancer survivors: a prospective cohort study
- 9 October 2026
- Published by Springer Nature in Journal of Cancer Survivorship
- p. 1-12
Frailty and risk of common chronic diseases among cancer survivors: a prospective cohort study
- Open Access
The impact of the SYNTAX score on the incidence of in-hospital cardiac arrest in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a retrospective cohort study
Background: The SYNTAX score (SS) quantifies the severity and complexity of coronary artery lesions and serves as an independent predictor of major adverse cardiovascular events and mortality in patients with acute coronary syndrome (ACS). However, few studies have examined the association between SS and in-hospital cardiac arrest (IHCA) in this population. Therefore, this study aims to elucidate the relationship between SS and the incidence of IHCA in patients with ACS. Methods: This study consecutively enrolled 3,224 patients undergoing percutaneous coronary intervention (PCI). Logistic regression and restricted cubic spline (RCS) analyses were employed to examine the association between SS and the incidence of IHCA. Participants were stratified into three groups based on SS: Group T1 (SS ≤ 10, N = 1,097), Group T2 (10 < SS ≤ 18, N = 1,089), and Group T3 (SS > 18, N = 1,038). The primary endpoint was the incidence of IHCA. Results: The overall incidence of IHCA was 4% (N=147). After adjusting for covariates, SS was significantly associated with the incidence of IHCA in ACS patients treated with PCI (OR = 1.0400; 95% confidence interval (CI) = 1.0200–1.0700; p < 0.001). Compared with the T1 group, the T3 group exhibited an increased risk of IHCA (OR = 2.1800; 95% CI = 1.2900–3.6900; p = 0.0040). Subgroup analyses revealed that, after covariate adjustment, patients with ST-segment elevation myocardial infarction (STEMI) had an increased risk of IHCA (OR = 1.0700; 95% CI = 1.0300–1.1100; p < 0.001). Similarly, both patients with diabetes mellitus (DM) (OR = 1.0400; 95% CI = 1.000–1.0700; p = 0.0270) and those without DM (OR = 1.0600; 95% CI = 1.0200–1.1000; p = 0.0020) showed an increased risk. Furthermore, elderly patients (≥60 years) (OR = 1.0300; 95% CI = 1.0100–1.0700; p = 0.0210) and non-elderly patients (p = 0.0470) had an increased risk, as did male patients (OR = 1.0500; 95% CI = 1.0200–1.0700; p = 0.0020). RCS analysis indicated a dose-response relationship between IHCA incidence and SS (nonlinear p -value = 0.906), with the risk of IHCA increasing when SS exceeded 23.975. Incorporating SS into the baseline risk model improved the predictive value for IHCA incidence in ACS patients undergoing PCI (Net reclassification improvement [NRI]: 0.3537 [0.1906–0.5167], p < 0.001; Integrated discriminant improvement [IDI]: 0.0104 [0.0025–0.0183], p = 0.0097). Conclusions: Among patients with ACS undergoing PCI, SS is significantly associated with the incidence of IHCA. Consequently, SS may serve as an effective predictor of IHCA in this population.
Open AccessThe impact of the SYNTAX score on the incidence of in-hospital cardiac arrest in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a retrospective cohort study
Background: The SYNTAX score (SS) quantifies the severity and complexity of coronary artery lesions and serves as an independent predictor of major adverse cardiovascular events and mortality in patients with acute coronary syndrome (ACS). However, few studies have examined the association between SS and in-hospital cardiac arrest (IHCA) in this population. Therefore, this study aims to elucidate the relationship between SS and the incidence of IHCA in patients with ACS. Methods: This study consecutively enrolled 3,224 patients undergoing percutaneous coronary intervention (PCI). Logistic regression and restricted cubic spline (RCS) analyses were employed to examine the association between SS and the incidence of IHCA. Participants were stratified into three groups based on SS: Group T1 (SS ≤ 10, N = 1,097), Group T2 (10 < SS ≤ 18, N = 1,089), and Group T3 (SS > 18, N = 1,038). The primary endpoint was the incidence of IHCA. Results: The overall incidence of IHCA was 4% (N=147). After adjusting for covariates, SS was significantly associated with the incidence of IHCA in ACS patients treated with PCI (OR = 1.0400; 95% confidence interval (CI) = 1.0200–1.0700; p < 0.001). Compared with the T1 group, the T3 group exhibited an increased risk of IHCA (OR = 2.1800; 95% CI = 1.2900–3.6900; p = 0.0040). Subgroup analyses revealed that, after covariate adjustment, patients with ST-segment elevation myocardial infarction (STEMI) had an increased risk of IHCA (OR = 1.0700; 95% CI = 1.0300–1.1100; p < 0.001). Similarly, both patients with diabetes mellitus (DM) (OR = 1.0400; 95% CI = 1.000–1.0700; p = 0.0270) and those without DM (OR = 1.0600; 95% CI = 1.0200–1.1000; p = 0.0020) showed an increased risk. Furthermore, elderly patients (≥60 years) (OR = 1.0300; 95% CI = 1.0100–1.0700; p = 0.0210) and non-elderly patients (p = 0.0470) had an increased risk, as did male patients (OR = 1.0500; 95% CI = 1.0200–1.0700; p = 0.0020). RCS analysis indicated a dose-response relationship between IHCA incidence and SS (nonlinear p -value = 0.906), with the risk of IHCA increasing when SS exceeded 23.975. Incorporating SS into the baseline risk model improved the predictive value for IHCA incidence in ACS patients undergoing PCI (Net reclassification improvement [NRI]: 0.3537 [0.1906–0.5167], p < 0.001; Integrated discriminant improvement [IDI]: 0.0104 [0.0025–0.0183], p = 0.0097). Conclusions: Among patients with ACS undergoing PCI, SS is significantly associated with the incidence of IHCA. Consequently, SS may serve as an effective predictor of IHCA in this population.
- Open Access
- 1 August 2026
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 16 (4) , 64
Comparison of safety and long-term outcomes of retrograde chronic total occlusion percutaneous coronary intervention in patients with vs. without diabetes mellitus: a retrospective cohort study
Background: The safety profile and long-term outcomes of retrograde percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in patients with diabetes mellitus (DM) remain inadequately characterized. We evaluated procedural and extended follow-up results in this cohort. Methods: This single-center retrospective study enrolled adults undergoing retrograde CTO-PCI; individuals with incomplete data, malignancy, or end-stage renal disease were excluded. Primary and secondary outcomes were all-cause mortality and major adverse cardiovascular events (MACE), respectively. Intergroup comparisons used standard univariate tests. Cumulative hazard functions were estimated via the Nelson-Aalen method, and multivariable Cox proportional hazards models were performed to adjust for clinical confounders and identify variables associated with MACE. Results: In total, 836 patients met the criteria. Success rates for collateral channel (CC) tracking (92.0% in the DM group vs. 95.0% in the non-DM group, P=0.08), retrograde PCI success (87.4% in the DM group vs. 91.3% in the non-DM group, P=0.07), and final recanalization (89.4% in the DM group vs. 92.0% in the non-DM group, P=0.20) were statistically similar. In-hospital complication rates were minimal and comparable (all P>0.05). Follow-up data were obtained for 767 patients (91.7%) over a median of 1,041 days. Patients with DM experienced a significantly higher risk of MACE (19.2% in the DM group vs. 13.9% in the non-DM group, P=0.046), primarily driven by increased all-cause mortality (9.3% in the DM group vs. 4.5% in the non-DM group, P=0.007) and cardiac death (7.4% in the DM group vs. 2.2% in the non-DM group, PConclusions: Retrograde PCI is technically safe and effective in CTO patients with DM. However, this cohort carries a significantly higher long-term risk of mortality and MACE than non-diabetic counterparts, necessitating intensified post-procedural risk-factor management.
- 1 August 2026
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 16 (4) , 64
Open AccessComparison of safety and long-term outcomes of retrograde chronic total occlusion percutaneous coronary intervention in patients with vs. without diabetes mellitus: a retrospective cohort study
Background: The safety profile and long-term outcomes of retrograde percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in patients with diabetes mellitus (DM) remain inadequately characterized. We evaluated procedural and extended follow-up results in this cohort. Methods: This single-center retrospective study enrolled adults undergoing retrograde CTO-PCI; individuals with incomplete data, malignancy, or end-stage renal disease were excluded. Primary and secondary outcomes were all-cause mortality and major adverse cardiovascular events (MACE), respectively. Intergroup comparisons used standard univariate tests. Cumulative hazard functions were estimated via the Nelson-Aalen method, and multivariable Cox proportional hazards models were performed to adjust for clinical confounders and identify variables associated with MACE. Results: In total, 836 patients met the criteria. Success rates for collateral channel (CC) tracking (92.0% in the DM group vs. 95.0% in the non-DM group, P=0.08), retrograde PCI success (87.4% in the DM group vs. 91.3% in the non-DM group, P=0.07), and final recanalization (89.4% in the DM group vs. 92.0% in the non-DM group, P=0.20) were statistically similar. In-hospital complication rates were minimal and comparable (all P>0.05). Follow-up data were obtained for 767 patients (91.7%) over a median of 1,041 days. Patients with DM experienced a significantly higher risk of MACE (19.2% in the DM group vs. 13.9% in the non-DM group, P=0.046), primarily driven by increased all-cause mortality (9.3% in the DM group vs. 4.5% in the non-DM group, P=0.007) and cardiac death (7.4% in the DM group vs. 2.2% in the non-DM group, PConclusions: Retrograde PCI is technically safe and effective in CTO patients with DM. However, this cohort carries a significantly higher long-term risk of mortality and MACE than non-diabetic counterparts, necessitating intensified post-procedural risk-factor management.
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e048476
Association of Dietary Patterns and Genetic Risk With Cardiovascular Disease in UK Biobank Cancer Survivors
Background: The extent to which diet influences cardiovascular risk in survivors of cancer is not well established. We therefore assessed how adherence to various dietary patterns relates to the development of cardiovascular disease (CVD) in this population. Method: This study included 10 414 survivors of cancer from the UK Biobank who were free of CVD and had completed at least two 24‐hour dietary recalls. Adherence at baseline to the Alternative Healthy Eating Index 2010 (AHEI‐2010), alternate Mediterranean diet, dietary approaches to stop hypertension, and EAT‐Lancet diet was examined in relation to incident CVD, and Cox models were used to derive hazard ratios (HRs) with 95% CIs for CVD incidence. Results: The mean age of participants was 59.49±7.00 years, and 37% were men in our study. Over a median follow‐up of 13.12 years, 1331 incident CVD events were documented. In the fully adjusted model, the HRs for the highest versus lowest tertiles of adherence were 0.83 (95% CI, 0.72–0.97) for alternate Mediterranean diet, 0.76 (95% CI, 0.66–0.87) for AHEI‐2010, 0.82 (95% CI, 0.72–0.94) for dietary approaches to stop hypertension, and 0.85 (95% CI, 0.74–0.97) for EAT‐Lancet. Specifically, higher adherence to the alternate Mediterranean diet, AHEI‐2010, dietary approaches to stop hypertension, and EAT‐Lancet diets was associated with lower risks of ischemic heart disease (HR, 0.77–0.85), while the AHEI‐2010, dietary approaches to stop hypertension, and EAT‐Lancet diets were also linked to reduced risk of heart failure (HR, 0.74–0.88) and the AHEI‐2010 and EAT‐Lancet diets with lower stroke risk (HR, 0.81–0.83). No significant interaction between the genetic risk of CVD and diet pattern was observed. Conclusions: These results indicate that following a healthy diet is linked to a reduced risk of CVD among survivors of cancer, regardless of their genetic risk.
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e048476
Open AccessAssociation of Dietary Patterns and Genetic Risk With Cardiovascular Disease in UK Biobank Cancer Survivors
Background: The extent to which diet influences cardiovascular risk in survivors of cancer is not well established. We therefore assessed how adherence to various dietary patterns relates to the development of cardiovascular disease (CVD) in this population. Method: This study included 10 414 survivors of cancer from the UK Biobank who were free of CVD and had completed at least two 24‐hour dietary recalls. Adherence at baseline to the Alternative Healthy Eating Index 2010 (AHEI‐2010), alternate Mediterranean diet, dietary approaches to stop hypertension, and EAT‐Lancet diet was examined in relation to incident CVD, and Cox models were used to derive hazard ratios (HRs) with 95% CIs for CVD incidence. Results: The mean age of participants was 59.49±7.00 years, and 37% were men in our study. Over a median follow‐up of 13.12 years, 1331 incident CVD events were documented. In the fully adjusted model, the HRs for the highest versus lowest tertiles of adherence were 0.83 (95% CI, 0.72–0.97) for alternate Mediterranean diet, 0.76 (95% CI, 0.66–0.87) for AHEI‐2010, 0.82 (95% CI, 0.72–0.94) for dietary approaches to stop hypertension, and 0.85 (95% CI, 0.74–0.97) for EAT‐Lancet. Specifically, higher adherence to the alternate Mediterranean diet, AHEI‐2010, dietary approaches to stop hypertension, and EAT‐Lancet diets was associated with lower risks of ischemic heart disease (HR, 0.77–0.85), while the AHEI‐2010, dietary approaches to stop hypertension, and EAT‐Lancet diets were also linked to reduced risk of heart failure (HR, 0.74–0.88) and the AHEI‐2010 and EAT‐Lancet diets with lower stroke risk (HR, 0.81–0.83). No significant interaction between the genetic risk of CVD and diet pattern was observed. Conclusions: These results indicate that following a healthy diet is linked to a reduced risk of CVD among survivors of cancer, regardless of their genetic risk.
- Open Access
- 22 April 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Cardiometabolic health and all-cause and cause-specific mortality in the general US adult population
- 22 April 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Open AccessCardiometabolic health and all-cause and cause-specific mortality in the general US adult population
- Open Access
- 2 April 2026
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 42 (10) , e70205
Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ ARE Signaling in MI Rodent
This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐β/Smads signaling, whereas Mel treatment significantly upregulated Nrf2/ARE signaling in ischemia–reperfusion (IR) H9C2 cells (all P< 0.001). Additionally, simultaneously silencing TGF‐β and overexpression of Nrf2 in H9C2 cells significantly suppressed fibrotic and upregulated antioxidant signaling (all P< 0.001). Adult male Sprague–Dawley rats were categorized into groups 1 (sham‐operated‐control)/2 (AMI)/3 (AMI + DAPA)/4 (AMI + Mel)/5 (AMI + DAPA‐Mel), and the hearts were harvested by day 28. By day 28 after AMI induction, the LVEF was highest in group 1, lowest in group 2, and significantly higher in group 5 than in groups 3 and 4, but it did not differ between groups 3 and 4, whereas the LV systolic/diastolic dimensions exhibited an opposite pattern of LVEF among the groups (all P< 0.0001). The protein expressions of TGF‐β/Smads signaling exhibited an opposite pattern, whereas the protein expressions of Nrf2/ARE signaling displayed an identical pattern of LVEF among the groups (all P< 0.0001). The protein expressions of oxidative‐stress/DNA‐mitochondria damaged/inflammatory biomarkers and histopathological/anatomical findings demonstrated that the infarct and fibrotic areas/LV‐chamber dimensions/cardiomyocyte size exhibited an opposite manner of LVEF among the groups (all P< 0.0001). In conclusion, combined DAPA‐Mel therapy was superior to merely one for improving LVEF and inhibiting fibrosis/LV remodeling in AMI rodents.
- 2 April 2026
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 42 (10) , e70205
Open AccessEarly Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ ARE Signaling in MI Rodent
This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐β/Smads signaling, whereas Mel treatment significantly upregulated Nrf2/ARE signaling in ischemia–reperfusion (IR) H9C2 cells (all P< 0.001). Additionally, simultaneously silencing TGF‐β and overexpression of Nrf2 in H9C2 cells significantly suppressed fibrotic and upregulated antioxidant signaling (all P< 0.001). Adult male Sprague–Dawley rats were categorized into groups 1 (sham‐operated‐control)/2 (AMI)/3 (AMI + DAPA)/4 (AMI + Mel)/5 (AMI + DAPA‐Mel), and the hearts were harvested by day 28. By day 28 after AMI induction, the LVEF was highest in group 1, lowest in group 2, and significantly higher in group 5 than in groups 3 and 4, but it did not differ between groups 3 and 4, whereas the LV systolic/diastolic dimensions exhibited an opposite pattern of LVEF among the groups (all P< 0.0001). The protein expressions of TGF‐β/Smads signaling exhibited an opposite pattern, whereas the protein expressions of Nrf2/ARE signaling displayed an identical pattern of LVEF among the groups (all P< 0.0001). The protein expressions of oxidative‐stress/DNA‐mitochondria damaged/inflammatory biomarkers and histopathological/anatomical findings demonstrated that the infarct and fibrotic areas/LV‐chamber dimensions/cardiomyocyte size exhibited an opposite manner of LVEF among the groups (all P< 0.0001). In conclusion, combined DAPA‐Mel therapy was superior to merely one for improving LVEF and inhibiting fibrosis/LV remodeling in AMI rodents.
- Open Access
- 2 April 2026
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 64, 101917
A prediction model for the risk of developing HFpEF during hospitalization in patients with acute myocardial infarction
- 2 April 2026
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 64, 101917
Open AccessA prediction model for the risk of developing HFpEF during hospitalization in patients with acute myocardial infarction
- Open Access
- 28 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 198, 119279
Corrigendum to “Entresto protected the cardiomyocytes and preserved heart function in cardiorenal syndrome rat fed with high-protein diet through regulating the oxidative stress and Mfn2-mediated mitochondrial functional integrity” [Biomed. Pharmacother. 144 (2021) 112244]
- 28 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 198, 119279
Open AccessCorrigendum to “Entresto protected the cardiomyocytes and preserved heart function in cardiorenal syndrome rat fed with high-protein diet through regulating the oxidative stress and Mfn2-mediated mitochondrial functional integrity” [Biomed. Pharmacother. 144 (2021) 112244]
- Open Access
- 27 February 2026
- Published by Springer Nature in Nutrition Journal
- Vol. 25 (1)
Adherence to the EAT-Lancet diet and risk of chronic kidney disease among middle-aged and older adults: insights from two nationwide cohort studies
Adherence to the EAT-Lancet diet has been associated with a lower risk of adverse health outcomes. However, its relationship with chronic kidney disease (C
- 27 February 2026
- Published by Springer Nature in Nutrition Journal
- Vol. 25 (1)
Open AccessAdherence to the EAT-Lancet diet and risk of chronic kidney disease among middle-aged and older adults: insights from two nationwide cohort studies
Adherence to the EAT-Lancet diet has been associated with a lower risk of adverse health outcomes. However, its relationship with chronic kidney disease (C